5-氮杂-2’-脱氧胞苷序贯顺铂对MDA-MB-231细胞的影响  

Effect of sequential treatment of 5-aza-2’-deoxycytidine and cisplatin in MDA-MB-231 cells

作　　者：沈三弟[1] 陈卓荣[1] 肖高芳[2] 刘彦明[3] 黄湛[1] 罗智辉[1] 

机构地区：[1]粤北人民医院头颈乳腺外科,广东韶关512026 [2]粤北人民医院病理科,广东韶关512026 [3]粤北人民医院检验科,广东韶关512026

出　　处：《中华乳腺病杂志（电子版）》2013年第3期32-35,共4页Chinese Journal of Breast Disease(Electronic Edition)

基　　金：韶关市科技计划项目(2012CX/K72)

摘　　要：目的探讨5-氮杂-2’-脱氧胞苷(DAC)、顺铂(PDD)序贯应用对人三阴性乳腺癌细胞MDA-MB-231体外增殖、周期及凋亡的影响。方法实验分4组:对照组、DAC组(5μmol/LDAC处理)、PDD组(15μmol/LPDD处理)、DAC序贯PDD组(2.5μmol/LDAC处理24h,再用8μmol/LPDD处理48h)。分别用MTT法、流式细胞仪测定各组MDA-MB-231细胞的增殖、周期及凋亡,并用金氏公式来评价两药联合效应。结果 DAC序贯PDD组较DAC组、PDD组增殖抑制率高(P<0.01)。DAC序贯PDD组48h、72h的q值分别为1.12、1.17,两药联合有增效作用。DAC序贯PDD组G1、S期细胞减少,G2/M期细胞增多,DAC序贯PDD组较DAC组、PDD组细胞凋亡率高(P<0.01)。结论低剂量的DAC与PDD序贯应用可以抑制人三阴性乳腺癌MDA-MB-231细胞增殖,促进MDA-MB-231细胞凋亡。Objective To evaluate the effect of sequential use of 5-aza-2＇-deoxycytidine （DAC） and cisplatin（PDD） on the proliferation in vitro, cell cycle and apoptosis of triple-negative breast cancer（ TNBC ） cell line MDA-MB-231. Methods The cells were divided into 4 groups： control group, DAC group（ treated with 5 p.mol/L DAC ）, PDD group （treated with 15 μmol/L PDD）, DAC→PDD group（ treated with 2. 5 μmol/L DAC for 24 h and then 8 μmol/L PDD for 48 h ）. MTT and flow cytometry were used to determine the proliferation rate, cells cycles and cells apoptosis rate of MDA-MB-231 cells. Jin＇s formula was used to evaluate the combining effect of DAC and PDD. Results The proliferation rate of DAC→PDD group was higher than that of the other two groups（P〈0.01 ）. The q values of DAC→PDD group were 1.12 at 48 h, 1.17 at 72 h, which indicated the synergistic effect. In DAC→PDD group, the cells in G1 and S stage were decreased, and G2/M cells were increased. The cell apoptosis rate of DAC→PDD group was higher than that of the other two groups （P〈0. 01 ）. Conclusion The sequential use of DAC and PDD at a low dosage can inhibit the proliferation and promote the apoptosis of human TNBC ceils MDA-MB-231.

关 键 词：乳腺肿瘤 细胞增殖 细胞周期 细胞凋亡 5-氮杂-2’-脱氧胞苷 顺铂 

分 类 号：R737.9[医药卫生—肿瘤]